As cardiovascular diseases remain the leading cause of mortality worldwide,
a large number of clinical trials are under development, investigating the safety and
efficacy of RNA therapeutics in clinical conditions. Nanomedicine based drug delivery
systems are currently the new avenue for the treatment of CVDs, providing great
advantages to the treatment regime of CVDs. Currently, antisense therapy DNA- and
RNA-based and microRNAs are widely applied therapeutic strategies to regulate gene
expression and its effect on CVDs. In this review, different biological-based targeting
therapies for cardiovascular diseases and their outcomes are discussed.
Keywords: DNA, miRNA, Nanomedicine, Nanoparticles, RNA interference,
siRNA.